Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0 Trial of Hydroxychloroquine, an Inhibitor of Autophagy, in Patients With Stage III or IV Resectable Melanoma

NCT00962845 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT00962845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00962845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0 Trial of Hydroxychloroquine, an Inhibitor of Autophagy, in Patients With Stage III or IV Resectable Melanoma
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2010
Completion date
May 30, 2013
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)